Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Quality of care for heart patients does not improve in first year of ACO participation

Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.

Routine IR procedure could treat endometriosis.

Routine interventional procedure may present new endometriosis treatment option

Known to be extremely painful at times, many women with endometriosis consider flare-ups of the condition to be debilitating.

merger acquisition M&A business

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology

Boston Scientific hopes to officially launch its new IVL system in the first half of 2026.

Early pregnancy blood pressure patterns tied to hypertension risk years later

Researchers show certain blood pressure patterns during the first 20 weeks of pregnancy were more likely to develop into hypertension later in life. 

Heart Rhythm Advocates (HRA), the political advocacy wing of the Heart Rhythm Society (HRS).

Heart Rhythm Society legislative advocacy group raising funds for electrophysiology

This week, Heart Rhythm Advocates announced its establishment and called on cardiologists and EPs to support its efforts with membership and joining committees to guide efforts.

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, and a clinical professor of medicine at Wake Forest University School of Medicine, offers what he saw as the main takeaway messages in the ACC 2025 late breaking trials.

Key takeaways from ACC.25: Advances in cardiovascular science

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
 

Philippe Généreux, MD, presenting late-breaking clinical research on TAVR at ACC.25

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.

Sergio Raposeiras-Roubin, MD, presenting new data on TAVR and dapagliflozin at ACC.25 in Chicago

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.